[go: up one dir, main page]

ATE555794T1 - Heilmittel gegen hepatitis - Google Patents

Heilmittel gegen hepatitis

Info

Publication number
ATE555794T1
ATE555794T1 AT01904385T AT01904385T ATE555794T1 AT E555794 T1 ATE555794 T1 AT E555794T1 AT 01904385 T AT01904385 T AT 01904385T AT 01904385 T AT01904385 T AT 01904385T AT E555794 T1 ATE555794 T1 AT E555794T1
Authority
AT
Austria
Prior art keywords
hepatitis
remedies
virus
present
cell
Prior art date
Application number
AT01904385T
Other languages
English (en)
Inventor
Seima Itami
Tatsurou Shibui
Makoto Seki
Yoshihisa Yotsumoto
Yoshiharu Matsuura
Tatsuo Miyamura
Original Assignee
Mitsubishi Tanabe Pharma Corp
Jp Agency Of Nat Inst Of Infectious Deseases
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mitsubishi Tanabe Pharma Corp, Jp Agency Of Nat Inst Of Infectious Deseases filed Critical Mitsubishi Tanabe Pharma Corp
Application granted granted Critical
Publication of ATE555794T1 publication Critical patent/ATE555794T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/737—Sulfated polysaccharides, e.g. chondroitin sulfate, dermatan sulfate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1081—Togaviridae, e.g. flavivirus, rubella virus, hog cholera virus
    • C07K16/109—Hepatitis C virus; Hepatitis G virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
  • Steroid Compounds (AREA)
AT01904385T 2000-02-14 2001-02-13 Heilmittel gegen hepatitis ATE555794T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2000034906 2000-02-14
PCT/JP2001/000967 WO2001058459A1 (en) 2000-02-14 2001-02-13 Remedies for hepatitis c

Publications (1)

Publication Number Publication Date
ATE555794T1 true ATE555794T1 (de) 2012-05-15

Family

ID=18559171

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01904385T ATE555794T1 (de) 2000-02-14 2001-02-13 Heilmittel gegen hepatitis

Country Status (8)

Country Link
US (1) US7101551B2 (de)
EP (1) EP1256348B1 (de)
KR (1) KR20020091093A (de)
CN (1) CN100391469C (de)
AT (1) ATE555794T1 (de)
AU (1) AU2001232267A1 (de)
BR (1) BR0108499A (de)
WO (1) WO2001058459A1 (de)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7261893B2 (en) 2002-10-22 2007-08-28 Wyeth Neutralizing antibodies against GDF-8 and uses therefor
JP4749861B2 (ja) * 2003-08-28 2011-08-17 大日本住友製薬株式会社 抗ｃｄ８１抗体を有効成分として含有する炎症性腸疾患の予防または治療剤
WO2005095441A1 (ja) * 2004-03-31 2005-10-13 National Institute Of Advanced Industrial Science And Technology 上皮系細胞増殖促進剤
ES2545769T3 (es) 2005-04-18 2015-09-15 Amgen Research (Munich) Gmbh Anticuerpos neutralizantes del factor estimulante de colonias de granulocitos y macrófagos humano
ES2445695T3 (es) * 2008-05-02 2014-03-04 Novartis Ag Moléculas de unión con base en fibronectina mejorada y usos de las mismas
US9139825B2 (en) 2009-10-30 2015-09-22 Novartis Ag Universal fibronectin type III bottom-side binding domain libraries
CN103429265A (zh) 2010-05-25 2013-12-04 国家医疗保健研究所 用于治疗和预防hcv感染的抗包膜抗体和抗受体抗体组合物
JP6029470B2 (ja) * 2010-12-06 2016-11-24 大日本住友製薬株式会社 ヒトモノクローナル抗体
WO2013024157A2 (en) 2011-08-17 2013-02-21 INSERM (Institut National de la Santé et de la Recherche Médicale) Combinations of host targeting agents for the treatment and the prevention of hcv infection
WO2013024156A2 (en) 2011-08-17 2013-02-21 INSERM (Institut National de la Santé et de la Recherche Médicale) Combinations of anti-hcv-entry factor antibodies and interferons for the treatment and the prevention of hcv infection
WO2013024155A1 (en) 2011-08-17 2013-02-21 Inserm (Institut National De La Sante Et De La Recherche Medicale) Combinations of anti-hcv-entry factor antibodies and direct acting antivirals for the treatment and the prevention of hcv infection
WO2013024158A1 (en) 2011-08-17 2013-02-21 INSERM (Institut National de la Santé et de la Recherche Médicale) Combinations of protein kinase inhibitors and interferons or of protein kinase inhibitors and direct acting antivirals for the treatment and the prevention of hcv infection
WO2014033266A1 (en) 2012-08-31 2014-03-06 INSERM (Institut National de la Santé et de la Recherche Médicale) Anti-sr-bi antibodies for the inhibition of hepatitis c virus infection
WO2014068029A1 (en) 2012-10-31 2014-05-08 Takeda Gmbh Lyophilized formulation comprising gm-csf neutralizing compound
AR093297A1 (es) 2012-10-31 2015-05-27 Amgen Res (Munich) Gmbh Formulacion liquida que comprende un compuesto neutralizante de gm-csf
RU2714919C2 (ru) 2013-08-30 2020-02-21 Такеда Гмбх Антитела, нейтрализующие gm-csf, для применения в лечении ревматоидного артрита или в качестве анальгетиков
EP3685842B1 (de) 2014-06-06 2022-08-31 Memorial Sloan-Kettering Cancer Center Gegen mesothelin gerichete chimäre antigenrezeptoren und verwendungen davon
US11542332B2 (en) 2016-03-26 2023-01-03 Bioatla, Inc. Anti-CTLA4 antibodies, antibody fragments, their immunoconjugates and uses thereof
BR112021000727A2 (pt) * 2018-07-20 2021-04-13 Surface Oncology, Inc. Composições anti-cd112r e métodos

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5574132A (en) * 1991-04-05 1996-11-12 Biochem Immunosystems Inc. Peptides and mixtures thereof for detecting antibodies to hepatitis C virus (HCV)
EP0697888B1 (de) * 1993-05-12 2003-09-17 Chiron Corporation Konserviertes Motiv der Hepatitis C Virus E2/NS1 Region
CN1044384C (zh) * 1994-08-25 1999-07-28 中国药品生物制品检定所 抗丙型肝炎病毒抗原单克隆抗体细胞株建立及其单克隆抗体
CN1072482C (zh) * 1996-11-08 2001-10-10 山东医科大学 低分子肝素脂质体喷胶剂及制备工艺
CA2304796C (en) * 1997-10-06 2013-12-03 Chiron S.P.A. Hepatitis c receptor protein cd81
EP1097172A1 (de) 1998-07-21 2001-05-09 Genmab A/S Anti-hepatitis c virus antikörper und verwendung davon
AU1462300A (en) 1998-11-05 2000-05-22 Board Of Trustees Of The Leland Stanford Junior University Human pan-hcv human monoclonal antibodies
WO2001094571A1 (fr) 2000-06-08 2001-12-13 Mitsubishi Pharma Corporation Vecteur d'expression permettant le criblage de cellules a haute expression de proteine de recombinaison, transformant a haute expression de proteine de recombinaison, et leur utilisation

Also Published As

Publication number Publication date
EP1256348B1 (de) 2012-05-02
US7101551B2 (en) 2006-09-05
KR20020091093A (ko) 2002-12-05
EP1256348A4 (de) 2005-07-27
CN100391469C (zh) 2008-06-04
US20030157132A1 (en) 2003-08-21
EP1256348A1 (de) 2002-11-13
WO2001058459A1 (en) 2001-08-16
CN1423561A (zh) 2003-06-11
BR0108499A (pt) 2003-03-11
AU2001232267A1 (en) 2001-08-20

Similar Documents

Publication Publication Date Title
ATE555794T1 (de) Heilmittel gegen hepatitis
PT1169339E (pt) Peptidos macrociclicos activos contra o virus da hepatite c
WO2004011478A3 (en) Anti-viral 7-deaza d-nucleosides and uses thereof
DE50102597D1 (de) Arzneimittel gegen virale erkrankungen
EA200700243A1 (ru) Способы лечения гепатита с
EP1673385A4 (de) Makrocyclische peptide mit wirkung gegen das hepatitis-c-virus
BRPI0415883A (pt) compostos e composições de nucleosìdeo para o tratamento de infecções virais
NO20051969L (no) Nukleosidderivater for behandling av hepatitt C virusinfeksjon.
BR0309581A (pt) Derivados de nucleosìdeo para tratamento de infecção por vìrus de hepatite c
GEP20104956B (en) Compounds for inhibiting hepatitis c viral replication and use thereof
WO2007001406A3 (en) Aryl-containing macrocyclic compounds
WO2001077091A3 (en) Ns5b hcv polymerase inhibitors
ECSP045300A (es) Antígenos virales
WO2009039246A3 (en) Methods of treating a flaviviridae family viral infection, compositions for treating a flaviviridae family viral infection, and screening assays for identifying compositions for treating a flaviviridae family viral infection
MXPA02012443A (es) Profarmaco en 3'' de 2'-desoxi-beta-l-nucleosidos.
ID27457A (id) Komposisi untuk pengobatan hiv dan infeksi virus lainnya
BR0305259A (pt) Inibidores de hcv ns5b polimerase
WO2007084413A3 (en) Methods for treating hepatitis c
ECSP056181A (es) Compuestos Inhibidores de la Hepatitis C
WO2010047830A3 (en) Agents for hcv treatment
WO2003055896A3 (en) Anti-viral 7-deaza l-nucleosides
DK1387681T3 (da) Anvendelse af castanosperinderivater til behandling af hepatitis C
PT1299395E (pt) Oxazinoquinolonas uteis para o tratamento de infeccoes provocadas por virus
WO2002062959A3 (en) Hepatitis b virus treatment
AU7602800A (en) Hepatitis c virus envelope two protein (e2) which lacks all or part of the hypervariable region one (hvr1), corresponding nucleic acids, chimeric viruses and uses thereof